Respiratory Syncytial Virus

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

New research highlights the effectiveness and safety of RSV vaccines for older adults, revealing critical insights into vaccination benefits and risks.

Administration during peak vaccine effectiveness provides maximal protective benefit

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

New research shows adults with RSV-ARI may face significantly higher mortality and health complications, emphasizing the need for targeted vaccination strategies.

New research reveals how aging weakens immune responses to RSV in older adults, increasing severity and hospitalization risks.

The recommendations are not considered to be final until they are published in the Morbidity and Mortality Weekly Report.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

A significant portion of unvaccinated individuals were open to future vaccination.

Prioritizing preventive measures for high-risk individuals would effectively address half of RSV hospitalizations.

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Adults with asthma or COPD face a heightened risk of RSV-related illness.

RSV vaccine acceptance among older adults is significantly influenced by perceived benefits.

RSV infection resulted in higher costs among specific age groups, especially patients aged 70 to 80 years.

Pharmacists play a crucial role in understanding and responding to these developments, ensuring patients remain informed about the latest advancements and potential threats.

RSV poses a significant threat to high-risk adults, but effective vaccines offer strong protection, highlighting the need for increased vaccination rates and education.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

S-337395 demonstrated an 88.4% reduction in viral load and had a statistically significant improvement in clinical symptoms scores.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

mRNA-1345 (mRESVIA; Moderna) has the potential to significantly transform the RSV disease state in 2025, according to data analysts.

These drugs are set to revolutionize their respective disease states in 2025.

Despite these concerns, experts have emphasized that the benefits of RSV vaccination outweigh potential risks for older adults, who are at heightened risk of severe RSV-related illness.

Approximately 61% of individuals said respiratory syncytial virus (RSV vaccination for adults 60 years and older is effective.

Immunocompromised older adults developed fewer antibodies against RSV following vaccination compared with immunocompetent individuals.

Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.

Rates of GBS were similar between Arexvy and Abrysvo, at 0.12% and 0.11% of total reported events, respectively.

Reduced hospital masking and testing policies increased rates of hospital-onset respiratory infections, including RSV.

Researchers developed a method to stabilize respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) fusion (F) proteins, advancing potential vaccines for both viruses.